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CONTEXT AND OBJECTIVE: The safety and 
effi cacy of drug-eluting stents reduce the need 
for surgical revascularization. The objective of 
the present study was to investigate whether 
paclitaxel or rapamycin-eluting stent are effec-
tive in avoiding the need for coronary-artery 
bypass grafting.
METHODS: This was a systematic review of the 
literature using the methodology of the Cochrane 
Collaboration. The type of study considered was 
controlled randomized trials; the type of interven-
tion was drug-eluting or bare-metal stents; and the 
main outcome investigated was coronary-artery 
bypass grafting.
RESULTS: The ten studies included in this sys-
tematic review did not show any statistically 
signifi cant difference between the drug-eluting 
stents and the bare-metal stents with regard to 
the outcome of coronary-artery bypass grafting 
(confi dence interval: 0.31 to 1.42).
CONCLUSION: The surgical revascularization 
rate was not reduced by the use of drug-elut-
ing stents.
KEY WORDS: Angina pectoris. Coronary artery 
bypass. Percutaneous transluminal coronary 
angioplasty. Myocardial revascularization. 
Thoracic surgery.
INTRODUCTION
Restenosis following stent implanta-
tion is a consequence of neointimal hyper-
plasia resulting from the proliferation and 
migration of smooth-muscle cells and 
production of extracellular matrix. The 
medical literature shows that drug-eluting 
stents are agents capable of interrupting 
cell replication and that stents show prom-
ise in inhibiting neointimal hyperplasia.1-3 
There are two drugs commonly used: pa-
clitaxel, a lipophilic molecule derived from 
the Pacific yew tree Taxus brevifolia that is 
capable of inhibiting cell division, motility, 
activation, secretory processes and signal 
transduction; and sirolimus (rapamycin), 
a cytostatic macrocyclic lactone with both 
anti-inflammatory and antiproliferative 
properties.4 Both restenosis and percutane-
ous revascularization are outcomes in all of 
the published studies. Drug-eluting stents 
appear to be a possibility for treating the 
coronary arterial disease, as a replacement 
for the existing therapies, but there is no 
proof of their effectiveness and safety. No 
differences in vital outcomes like mortal-
ity and myocardial infarction have been 
found between drug-eluting stents and 
bare-metal stents. However, such reports 
have not indicated whether there is any 
decrease in the need for coronary-artery 
bypass grafting (CABG). 
OBJECTIVE
The objective of the present study was to 
investigate whether paclitaxel or rapamycin-
eluting stents are effective in avoiding the 
need for CABG. 
METHODS
The search strategy involved the follow-
ing: a) online databases: Literatura Latino-
Americana e do Caribe em Ciências da 
Saúde (Lilacs), Medical Literature Analysis 
and Retrieval System Online (Medline) and 
the Cochrane Library; b) manual search for 
studies; c) personal communication; and d) 
contact with the pharmaceutical industry. 
Two reviewers independently inspected the 
references of the studies found using this 
search strategy, and applied the inclusion 
criteria. Where disagreement occurred this 
was resolved by discussion or, if doubts 
remained, the full article was acquired for 
further inspection. An intention-to-treat 
analysis was done. The relative risks (RR) 
and their respective 95% confi dence in-
tervals (CI) were calculated based on the 
random effects model, since this takes into 
account any differences between studies, 
even if there is no statistically signifi cant 
heterogeneity. The data were inspected to 
see whether analysis using a fi xed effects 
model would make any substantive differ-
ence. The methodological quality of the 
trials selected was assessed using the criteria 
described in the Cochrane Handbook.5 The 
Jadad scale6 was also used.
Inclusion criteria
Type of study: Only randomized control-
led trials were considered. The adequacy of 
allocation concealment was assessed as shown 
in Table 1. Only studies from categories A and 
B were considered for inclusion.
Type of participants: patients with rest-
enosis post-stent implantation.
Type of interventions: drug-eluting stents 
versus bare-metal stents.
Type of outcome: coronary artery by-
pass grafting.
After locating all of the eligible studies, 
the data were summarized in a meta-analysis. 
This systematic review was approved by the 
ethics committee of Universidade Federal 
de São Paulo.
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Included studies 
The search strategy found 329 studies. Of 
these, 10 studies met the inclusion criteria that 
had been established. The excluded studies did 
not meet one or more of the inclusion criteria, 
particularly with regard to randomization and 
outcome. There was total agreement between 
the reviewers.
Studies on paclitaxel-eluting stents: 
Taxus I (Grube et al.),7 Taxus II (Colombo et 
al.),8 Taxus IV (Stone et al.),9 European evaLU-
ation of pacliTaxel-Eluting Stent [ELUTES] 
(Gershlick et al.),10 Asian Paclitaxel-Eluting 
Stent [ASPECT] (Park et al.),11 and RX 
ACHIEVE Drug-Eluting Coronary Stent Sys-
tem In the Treatment of Patients with De NoVo 
NativE CoronaRy Lesions [DELIVER].12 
Studies on sirolimus (rapamycin)-eluting 
stents: Randomized study with the sirolimus-
eluting Velocity Balloon-Expandable Stent 
[RAVEL] (Morice et al.),13 SIRolImUS-
Eluting Stent in De Novo Native Coronary 
Lesions [SIRIUS] (Moses et al),14 Canada-
SIRolImUS-Eluting Stent in De Novo Native 
Coronary Lesions [C-SIRIUS] (Schampaert 
et al.),15 and Europe-SIRolImUS-Eluting 
Stent in De Novo Native Coronary Lesions 
[E-SIRIUS] (Schofer et al.).16 
RESULTS
With regard to the outcome “need for coro-
nary bypass grafting”, the analysis was done in 
three subgroups: 1) polymer-based paclitaxel-
eluting stents; 2) polymer-free paclitaxel-elut-
ing stents; 3) sirolimus (rapamycin)-eluting 
stents. There were 2,455 participants in the 
experimental group and 2,437 in the control 
group. In total, 10 included studies reported 
this outcome. Only one study, Taxus IV, was 
favorable to the experimental group. The data 
from each study were analyzed using the Rev-
Man software.17 The resulting meta-analysis did 
not fi nd any statistically signifi cant difference 
between the drug-eluting stents and the bare-
metal stents: relative risk = 0.67; confi dence 
interval: 0.31 to 1.42 (Figure 1 – RevMan 
– Statistical analysis).
The following other outcomes were also 
analyzed in this study:
Thrombosis: ten studies; none of them 
found any statistical difference for any group. 
Meta-analysis: relative risk = 1.1; confi dence 
interval: 0.48 to 2.12.  
Mortality: ten studies; none of them 
found any statistical difference for any group. 
Meta-analysis: relative risk = 1.23; confi dence 
interval: 0.70 to 2.17.  
Myocardial infarction: ten studies; none 
of them found any statistical difference for 
Table 1. Adequacy of allocation concealment of randomized controlled trial 
included
Risk of Bias Interpretation Relationships to individual criteria
A. Low risk of bias Plausible bias unlikely to seriously alter the results All of the criteria met
B. Moderate risk of bias Plausible bias that raises some doubt about the results One or more criteria partly met
C. High risk of bias Plausible bias that seriously weakens confi dence in the results One or more criteria not met
Figure 1. Meta-analysis — coronary-artery bypass grafting.
any group. Meta-analysis: risk relative = 0.84; 
confi dence interval: 0.61 to 1.17.  
Percutaneous revascularization: ten stud-
ies; seven favorable to the experimental group 
and three without any statistical difference for 
any group. Meta-analysis: relative risk = 0.32; 
confi dence interval: 0.22 to 0.48; favorable to 
the experimental group.
Restenosis: ten studies; seven favorable 
to the experimental group and three with-
out any statistical difference for any group. 
Meta-analysis: relative risk = 0.30; confi dence 
interval: 0.21 to 0.43; favorable to the experi-
mental group.
DISCUSSION 
This systematic review shows that there is 
no advantage in eluting stent over bare-metal 
stent. The literature shows that the trauma to 
the vessel wall that is caused by stent implanta-
tion triggers an infl ammatory endothelial re-
sponse, independent of the presence or absence 
of a drug in this stent. This initial infl ammatory 
process is followed by a restenosis process.18 
Comparison between balloon angioplasty and 
coronary stenting shows that the infl ammatory 
process is less severe in balloon angioplasty, 
while in coronary stenting early neutrophil 
recruitment is followed by prolonged and abun-
dant recruitment of macrophages within the 
neointima.19,20 After stenting, several infl amma-
tory markers are released21-23 and their presence 
is associated with subsequent poor prognosis.24 
Adverse late clinical outcomes are linked with 
the magnitude of the systemic infl ammation. 
Patients may be risk-stratifi ed according to 
their concentrations of infl ammatory mark-
ers.25 Endothelial function becomes altered, 
thereby generating cytokine hypersecretion 
that preserves the infl ammatory process and 
leads to changes in the quantities of endothelial 
mediators released, which may decrease the 
nitric oxide levels (vasodilatation) or increase 
the endothelin-1 levels (vasoconstriction).26,27 
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Studies have shown that drug-eluting stents 
may exacerbate the inflammatory process, 
such that they may accentuate the restenosis 
process at the stent extremities28 and boost the 
strength of some platelet agonists, thus promot-
ing thrombus formation.29 Moreover, it has 
been demonstrated that sirolimus (rapamycin) 
reduces the production of nitric oxide.30 
All the transformations following stent 
implantation may persist for months and 
years. Clinically, there may or may not be any 
symptoms, but the important point is that 
these alterations exist and impair the clinical 
treatment. Consequently, it can be deduced 
that surgical revascularization in patients who 
have already been revascularized with stents, 
and whose hearts present chronic infl amma-
tory processes, will not have the same result 
as would be achieved in a heart that had never 
previously been revascularized with stents. In 
spite of the signifi cant differences in all res-
tenosis measurements, which were favorable 
to paclitaxel and rapamycin-eluting stents, the 
surgical revascularization rate was similar in 
the experimental and control groups. 
This was confi rmed at the recent World 
Congress of Cardiology held in Spain in Sep-
tember 2006. A meta-analysis with four years 
of follow-up was presented at that congress31,32 
(the published studies included in our systemat-
ic review had one-year follow-ups), in which the 
outcomes were similar to those presented in our 
systematic review, with the addition of other 
data that suggested that there was increased 
noncardiac mortality and a higher cancer rate in 
the experimental group. These poor outcomes 
confi rm all of the infl ammatory alterations that 
originate from stent implantation and their 
persistent disastrous consequences.
Taking all these facts together, it has to 
be accepted that the clinical benefi ts from 
drug-eluting stents with regard to target vessel 
restenosis and target vessel revascularization 
have been overestimated and that they do not 
offer safety, effi cacy and effectiveness. 
CONCLUSION
In the present study, paclitaxel or rapamy-
cin-eluting stent did not show any statistically 
signifi cant difference with regard to avoiding 
the need for coronary-artery bypass grafting, 
or in relation to myocardial infarction or 
death from cardiac causes, in comparison with 
bare-metal stent. 
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RESUMO
O uso de stents recobertos com paclitaxel ou rapamicina diminui o número de cirurgias de 
revascularização cardíaca quando comparado aos stents convencionais? 
CONTEXTO E OBJETIVO: A segurança e efi cácia dos stents recobertos com drogas reduz a necessidade 
da cirurgia de revascularização cardíaca. O objetivo foi verifi car se os stents recobertos com paclitaxel ou 
rapamicina são efetivos para evitar a necessidade de revascularização cirúrgica das coronárias.
MÉTODOS: Revisão sistemática da literatura usando a metodologia do Centro Cochrane. Tipos de estudos: 
estudos clínicos randomizados; tipo de intervenção: stents recobertos com drogas ou stents convencionais; 
desfecho principal: cirurgia de revascularização cardíaca. 
RESULTADOS: Os 10 estudos incluídos nesta revisão sistemática não mostram diferença estatisticamente 
signifi cante entre os stents recobertos com drogas e os stents convencionais no desfecho principal, com 
intervalo de confi ança de 0.31, 1.42.
CONCLUSÃO: A taxa de revascularização cardíaca não é reduzida pelo uso de stents recobertos com 
drogas.
PALAVRAS-CHAVE: Angina pectoris. Ponte de artéria coronária. Angioplastia transluminal percutânea 
coronária. Revascularização miocárdica. Cirurgia cardíaca.
